Show simple item record

dc.contributor.authorLener, T
dc.contributor.authorGimona, M
dc.contributor.authorAigner, L
dc.contributor.authorBoerger, V
dc.contributor.authorBuzas, E
dc.contributor.authorCamussi, G
dc.contributor.authorChaput, N
dc.contributor.authorChatterjee, D
dc.contributor.authorCourt, FA
dc.contributor.authordel Portillo, HA
dc.contributor.authorO'Driscoll, L
dc.contributor.authorFais, S
dc.contributor.authorFalcon-Perez, JM
dc.contributor.authorFelderhoff-Mueser, U
dc.contributor.authorFraile, L
dc.contributor.authorGho, YS
dc.contributor.authorGoergens, A
dc.contributor.authorGupta, RC
dc.contributor.authorHendrix, A
dc.contributor.authorHermann, DM
dc.contributor.authorHill, AF
dc.contributor.authorHochberg, F
dc.contributor.authorHorn, PA
dc.contributor.authorde Kleijn, D
dc.contributor.authorKordelas, L
dc.contributor.authorKramer, BW
dc.contributor.authorKraemer-Albers, E-M
dc.contributor.authorLaner-Plamberger, S
dc.contributor.authorLaitinen, S
dc.contributor.authorLeonardi, T
dc.contributor.authorLorenowicz, MJ
dc.contributor.authorLim, SK
dc.contributor.authorLotvall, J
dc.contributor.authorMaguire, CA
dc.contributor.authorMarcilla, A
dc.contributor.authorNazarenko, I
dc.contributor.authorOchiya, T
dc.contributor.authorPatel, T
dc.contributor.authorPedersen, S
dc.contributor.authorPocsfalvi, G
dc.contributor.authorPluchino, S
dc.contributor.authorQuesenberry, P
dc.contributor.authorReischl, IG
dc.contributor.authorRivera, FJ
dc.contributor.authorSanzenbacher, R
dc.contributor.authorSchallmoser, K
dc.contributor.authorSlaper-Cortenbach, I
dc.contributor.authorStrunk, D
dc.contributor.authorTonn, T
dc.contributor.authorVader, P
dc.contributor.authorvan Balkom, BWM
dc.contributor.authorWauben, M
dc.contributor.authorEl Andaloussi, S
dc.contributor.authorThery, C
dc.contributor.authorRohde, E
dc.contributor.authorGiebel, B
dc.date.accessioned2021-02-04T02:23:33Z
dc.date.available2021-02-04T02:23:33Z
dc.date.issued2015-01-01
dc.identifierpii: 30087
dc.identifier.citationLener, T., Gimona, M., Aigner, L., Boerger, V., Buzas, E., Camussi, G., Chaput, N., Chatterjee, D., Court, F. A., del Portillo, H. A., O'Driscoll, L., Fais, S., Falcon-Perez, J. M., Felderhoff-Mueser, U., Fraile, L., Gho, Y. S., Goergens, A., Gupta, R. C., Hendrix, A. ,... Giebel, B. (2015). Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper. JOURNAL OF EXTRACELLULAR VESICLES, 4 (1), https://doi.org/10.3402/jev.v4.30087.
dc.identifier.issn2001-3078
dc.identifier.urihttp://hdl.handle.net/11343/259664
dc.description.abstractExtracellular vesicles (EVs), such as exosomes and microvesicles, are released by different cell types and participate in physiological and pathophysiological processes. EVs mediate intercellular communication as cell-derived extracellular signalling organelles that transmit specific information from their cell of origin to their target cells. As a result of these properties, EVs of defined cell types may serve as novel tools for various therapeutic approaches, including (a) anti-tumour therapy, (b) pathogen vaccination, (c) immune-modulatory and regenerative therapies and (d) drug delivery. The translation of EVs into clinical therapies requires the categorization of EV-based therapeutics in compliance with existing regulatory frameworks. As the classification defines subsequent requirements for manufacturing, quality control and clinical investigation, it is of major importance to define whether EVs are considered the active drug components or primarily serve as drug delivery vehicles. For an effective and particularly safe translation of EV-based therapies into clinical practice, a high level of cooperation between researchers, clinicians and competent authorities is essential. In this position statement, basic and clinical scientists, as members of the International Society for Extracellular Vesicles (ISEV) and of the European Cooperation in Science and Technology (COST) program of the European Union, namely European Network on Microvesicles and Exosomes in Health and Disease (ME-HaD), summarize recent developments and the current knowledge of EV-based therapies. Aspects of safety and regulatory requirements that must be considered for pharmaceutical manufacturing and clinical application are highlighted. Production and quality control processes are discussed. Strategies to promote the therapeutic application of EVs in future clinical studies are addressed.
dc.languageEnglish
dc.publisherTAYLOR & FRANCIS LTD
dc.titleApplying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper
dc.typeJournal Article
dc.identifier.doi10.3402/jev.v4.30087
melbourne.affiliation.departmentBiochemistry and Molecular Biology
melbourne.affiliation.facultyMedicine, Dentistry & Health Sciences
melbourne.source.titleJournal of Extracellular Vesicles
melbourne.source.volume4
melbourne.source.issue1
dc.rights.licenseCC BY-NC
melbourne.elementsid1220902
melbourne.contributor.authorHill, Andrew
dc.identifier.eissn2001-3078
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record